Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Fallopian Tube Neoplasms 2Uveal Melanoma 1Thymoma 1Solitary Fibrous Tumor, Pleural 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoplasms, Plasma Cell 1Neoplasms 1Mesothelioma, Malignant 1Mediastinal Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myeloid, Acute 1Glioblastoma 1Eye Neoplasms 1Congenital Abnormalities 1Carcinoma, Ovarian Epithelial 1Carcinoma, Neuroendocrine 1Burkitt Lymphoma 1Brenner Tumor 1Bone Marrow Neoplasms 1

Interventions

Bortezomib 2posaconazole 1darinaparsin 1belinostat 1SCIO-469 1Lenalidomide 1Dexamethasone 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bone Marrow Neoplasms × belinostat × Clear all
NCT00431340 2015-07-08

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

Valerio Therapeutics

Phase 2 Terminated
4 enrolled
Plasma cell

Multiple Myeloma, Bone Marrow Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡